Allergen Case Study Solution
Valsartan may result in deterioration of renal function, including possible acute renal failure if used in combination with Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors). The use of Byvalson with ACE inhibitors or with aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Lastly Byvalson may cause an increased in serum lithium concentrations and lithium toxicity (Byvalson Interactions, 2016).
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Byvalson as soon as possible (Byvalson, 2016).
Symptomatic hypotension: may occur because of patients having an activated renin-angiotensin-aldosterone system. This should be corrected before Byvalson therapy is started. If excessive hypotension occurs patient should lay supine and IV fluids may be